Harvard Bioscience Inc.
HBIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.47M
Close$
$-3.07
151.1% downside
Current Fair Value
151.1% downsideOvervalued by 151.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $26.47 Million |
|---|---|
| Enterprise Value | $68.52 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-12.8 |
| Beta | 1.51 |
| Outstanding Shares | 4,473,000 |
Return
| Return on Equity | -97.39% |
|---|---|
| Return on Assets | -12.55% |
| Return on Invested Capital | 91.74% |
Valuation & Multiples
| P/E Ratio | -2.67 |
|---|---|
| PEG | 2.86 |
| Price to Sales | 0.32 |
| Price to Book Ratio | 3.01 |
| Enterprise Value to Revenue | 0.8 |
| Enterprise Value to EBIT | 1.38 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.72 |
| Debt to Equity | 4.89 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
$21.20 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.21
Average shareholder expectationRevenue Estimate
$21.45 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 35.44%▼ 3.89% |
|---|---|
| Total Invested | $7.72M▼ 33.85% |
| Investors Holding | 35▼ 29.00% |
ESG Score
No data